Patent ID: 8178495

Claim:
A therapeutic agent comprising a recombinant fusion protein with an elastin-like peptide (ELP) component and a glucagon-like peptide (GLP)-1 receptor agonist positioned at the N-terminal side of the ELP component, wherein the GLP-1 receptor agonist is GLP-1(7-37), GLP-1(7-36), or Exendin-4, each optionally having from 1 to 3 amino acid modifications independently selected from an insertion, a deletion, a truncation, and/or a substitution, and wherein the ELP component: (i) comprises 60 repeats of VPGXG (SEQ ID NO:3), where each X is V, G, or A at a ratio of 5:3:2; (ii) comprises 32 repeats of VPGXG (SEQ ID NO:3), where each X is K, V, or F at a ratio of 1:2:1; (iii) comprises 36 repeats of VPGXG (SEQ ID NO:3), where each X is K, V, or F at a ratio of 1:7:1, (iv) comprises 60 repeats of VPGXG (SEQ ID NO:3), where X is V, (v) comprises 30 repeats of AVGVP (SEQ ID NO:4), (vi) comprises 15 repeats of IPGXG (SEQ ID NO:5) where X is valine, or (vii) comprises 30 repeats of LPGXG (SEQ ID NO:7) where X is valine.